ARTICLE | Clinical News
Zealand Pharma preclinical data
June 29, 2015 7:00 AM UTC
In a mouse model of obesity, subcutaneous ZP-DI-70 every 3 days for 18 days reduced body weight by 4% at the 1 nmol/kg dose and by 13% at the 3 nmol/kg dose. In diabetic mice, a single subcutaneous in...